Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

424.99 -4.61 (-1.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
61 62 Next >
A Bull Market Is (Still) Coming: Here Are 3 Spectacular Stocks to Buy Sooner Rather Than Later
These stocks should be even bigger winners than they already are when a new bull market takes hold. 
Via The Motley Fool
3 Unstoppable Growth Stocks to Buy Right Now
These healthcare stocks show no signs of slowing down. 
Via The Motley Fool
1 Top Pharma Growth Stock to Buy Today and Hold Forever
Vertex's encouraging mix of recurring revenue and growth make it a leader. 
Via The Motley Fool
2 Top Biotech Stocks to Buy in September
There is rarely a bad time to buy stocks with massive upside potential. 
Via The Motley Fool
Could These Be Vertex Pharmaceuticals' Most Promising Candidates?
The biotech has no shortage of promising pipeline programs. 
Via The Motley Fool
September Rally? 3 Stocks to Buy Before Liftoff
September has the reputation as the worst performing month of the year, but these are stocks to buy now in anticipation of the rally to come. 
Via InvestorPlace
Expert Ratings for Vertex Pharmaceuticals
Via Benzinga
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
Exploring VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX)s quality characteristics.
Should you consider VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) for quality investing? 
Via Chartmill
3 Must-Know Tricks for Investing in Big Pharma Stocks
Using these tricks will help you appreciate where and when to invest. 
Via The Motley Fool
CRSP Stock Alert: What to Know as CRISPR Therapeutics Co-Founder Steps Down
With CRISPR Therapeutics announcing the departure of its co-founder, investors are also walking for the exits on CRSP stock. 
Via InvestorPlace
Healthcare Portfolio: A Mixed Market Looking for Value
Many healthcare stocks may be defensive in nature but if you are overweight the basic plays like the XLV or biotech funds like the Fidelity Biotechnology Fund you are trailing the market over the past... 
Via Talk Markets
3 Biotech Stocks to Invest In for Big-Time, Long-Term Gains
These biotech stocks to buy and hold offer tremendous upside blending long-term potential with healthcare advances. 
Via InvestorPlace
With a Prediction for a 70% Gain, Is Wall Street Too Optimistic About This Biotech Stock?
Big news could come in December and in March. 
Via The Motley Fool
The 3 Best Biotech Stocks to Buy Now: September 2023
With the biotech sector looking poised to continue its rally further, investors would do well to buy these stocks to capitalize. 
Via InvestorPlace
Peering Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
5 Surefire Stocks That Can Build Generational Wealth in 20 Years
Time is a trusted ally when you're invested in innovative businesses with sustained competitive advantages. 
Via The Motley Fool
2 Spectacular Growth Stocks You Can Buy in September With No Hesitation
There's no need for any anxiety with investing in these great stocks. 
Via The Motley Fool
The 3 Most Promising Biotech Stocks to Own Now
These top biotech stock picks with high and leading growth potential are must-owns for investors looking for high upside potential. 
Via InvestorPlace
Vertex to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference on September 13
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations
From Vertex Pharmaceuticals Incorporated
Via Business Wire
3 Top Growth Stocks I'd Buy Right Now Without Hesitation
These drugmakers are all leaders in their respective niches. 
Via The Motley Fool
Ross Stores, Vertex Pharmaceuticals And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed higher on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 10 Years
Via Benzinga
Got $600? Here are 3 No-Brainer Stocks You Absolutely Must Buy
You don't need a lot of money to make money when you invest in these no-brainer stocks at the start your investing career 
Via InvestorPlace
2 No-Brainer Biotech Stocks to Buy Right Now
These two companies make a compelling case for a high price. 
Via The Motley Fool
3 Clever Tricks to Find Winning Biotech Stocks
You'll need to dig into company details, but the effort is worthwhile. 
Via The Motley Fool
Gene Therapy Breakthroughs On The Horizon
Vertex Pharmaceuticals and CRISPR Therapeutics, alongside bluebird bio, are penning a new chapter in the story of gene therapy for sickle cell disease. 
Via Talk Markets
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years. 
Via Talk Markets
4 Superlative Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
With the Nasdaq Composite still 15% below its record-closing high, amazing deals are hiding in plain sight. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback